Vertex Pain Deal History & Licensing Activity
Vertex Pain is a large biotech headquartered in US. Over the past three years, Vertex Pain has been involved in 7 licensing and acquisition transactions, with a primary focus on mRNA (4 deals). The company currently has 39 active clinical trials, primarily in Rare Disease.
Deals (12mo)
3
Active Trials
39
Top Modality
mRNA
Focus Area
Rare Disease
Vertex Pain Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Vertex Pain in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| RNA therapeutics multi-product collaboration | Vertex Pharmaceuticals | mRNA | Preclinical | option | Jul 18, 2026 |
| Paltusotine | Vertex Pharmaceuticals | Small Molecules | Phase 3 | acquisition | Jul 8, 2026 |
| exagamglogene autotemcel | Vertex | Gene Therapy | Approved | collaboration | Mar 22, 2026 |
Vertex Pain Pipeline Focus
Therapeutic areas and modalities where Vertex Pain is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Vertex Pain Strategic Signals
Key indicators of Vertex Pain's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Vertex Pain Clinical Pipeline
Vertex Pain has 39 active clinical trials across 5 development phases.
4
Phase 4
2
Unknown
10
Phase 1
7
Phase 2
16
Phase 3
See How Your Asset Matches Vertex Pain's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
mRNA Benchmarks
Upfront, milestone, and royalty benchmarks for mrna deals
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Vertex Pain Licensing & Deal Activity
Vertex Pain is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 7 deals over the past three years, Vertex Pain ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Vertex Pain include Rare Disease (13 deals and trials), CNS Disorders (6 deals and trials), Option Deals (4 deals and trials), and Metabolic (3 deals and trials). In terms of modality, Vertex Pain has shown particular interest in mrna, gene therapy, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Vertex Pain and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Vertex Pain's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.